Scarica l'app Stockscreener
25.15
2.99%
0.73
Pre-mercato:
24.50
-0.65
-2.58%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SMMT Giù?
Forum
Previsione
Precedente Chiudi:
$24.42
Aprire:
$24.55
Volume 24 ore:
4.90M
Relative Volume:
1.83
Capitalizzazione di mercato:
$19.50B
Reddito:
$220.00K
Utile/perdita netta:
$-1.08B
Rapporto P/E:
-17.41
EPS:
-1.4448
Flusso di cassa netto:
$-326.53M
1 W Prestazione:
+27.86%
1M Prestazione:
+58.68%
6M Prestazione:
+19.82%
1 anno Prestazione:
+2.19%
Intervallo 1D:
$24.06
$25.48
Intervallo di 1 settimana:
$19.52
$25.48
Portata 52W:
$13.83
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Nome
Summit Therapeutics Inc
Settore
Industria
Telefono
305-203-2034
Indirizzo
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
25.15 | 19.50B | 220.00K | -1.08B | -326.53M | -1.4448 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2026-03-16 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Underweight |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Neutral |
| 2025-07-01 | Iniziato | UBS | Buy |
| 2025-06-11 | Iniziato | Leerink Partners | Underperform |
| 2025-03-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-03-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Iniziato | Evercore ISI | Outperform |
| 2025-02-28 | Iniziato | Goldman | Buy |
| 2025-01-08 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-06 | Iniziato | Jefferies | Buy |
| 2024-11-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-27 | Downgrade | Citigroup | Buy → Neutral |
| 2024-08-12 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-07 | Iniziato | Citigroup | Buy |
| 2024-03-26 | Iniziato | Stifel | Buy |
| 2018-06-28 | Downgrade | Janney | Buy → Neutral |
| 2018-05-02 | Iniziato | Janney | Buy |
| 2018-04-12 | Reiterato | Needham | Buy |
| 2018-02-13 | Iniziato | BTIG Research | Buy |
| 2018-01-04 | Iniziato | SunTrust | Buy |
| 2017-12-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-16 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-10-05 | Reiterato | Needham | Buy |
| 2016-09-16 | Iniziato | H.C. Wainwright | Buy |
| 2015-03-30 | Iniziato | Needham | Buy |
| 2015-03-30 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Summit Therapeutics Inc Borsa (SMMT) Ultime notizie
IonQ, Oklo, And Robinhood Are Among the Top 10 Large-Cap Gainers Last Week (April 13-April 17): Are the Others in Your Portfolio? - Benzinga
SMMT stock up 24% in three months: Here's what you need to know - MSN
Board seats, pay and equity plan on ballot at Summit Therapeutics (NASDAQ: SMMT) - Stock Titan
UBS reiterates Buy on Summit Therapeutics stock ahead of trial data - Investing.com Canada
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34 - Moomoo
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Summit Therapeutics has scarcity value in a crowded drug race: Analyst - MSN
Summit Therapeutics Inc Stock (SMMT) Moved Up by 12.03% on Apr 16: Drivers Behind the Movement - TradingKey
Summit Therapeutics (NASDAQ:SMMT) Stock Price Up 8.2%Still a Buy? - MarketBeat
SMMT Stock Up 24% in Three Months: Here's What You Need to Know - Yahoo Finance
Been holding for so long - Moomoo
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic - MSN
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing - Stock Traders Daily
What makes Summit Therapeutics (SMMT) one of the best large caps under $30 - MSN
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025 - ADVFN
Aug PostEarnings: Can Summit Therapeutics Inc be the next market leader2026 Investor Takeaways & Growth Focused Entry Point Reports - baoquankhu1.vn
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT) - ChartMill
Inflation Data: Can Summit Therapeutics Inc stock outperform in a bear marketBreakout Watch & Stock Portfolio Risk Control - baoquankhu1.vn
SMMT Analyst Rating: Citigroup Initiates Buy Coverage April 2026 - Meyka
Stifel initiates coverage of Summit Therapeutics (SMMT) with buy recommendation - MSN
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Sahm
Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst - Sahm
SMMT Upgraded to Buy by Citigroup on April 08, 2026 - Meyka
Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors - TipRanks
SMMT : POTENTIAL BOUNCEBACK Click Through The Up Coming Page (2dUA4zfHbg) - Mshale
SUMMIT THERAPEUTICS INC BIG TRADING SWING | SMMT STOCK Simply Click The Next Internet Page (JHLdCFn8fQ) - Mshale
Citigroup starts coverage of Summit Therapeutics Inc (SMMT), Apr 08 2026, Buy - Meyka
What's Going On With Summit Therapeutics Stock Wednesday?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
$Summit Therapeutics (SMMT.US)$ - Moomoo
Stifel Initiates Coverage on Summit Therapeutics (SMMT) with 'Bu - GuruFocus
Pullback Watch: Is Summit Therapeutics Inc forming higher highs and higher lowsQuarterly Portfolio Review & Low Drawdown Investment Ideas - baoquankhu1.vn
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
Tudor Investment Corp ET AL Takes $7.17 Million Position in Summit Therapeutics PLC $SMMT - MarketBeat
Stifel Initiates Coverage on Summit Therapeutics (SMMT) with 'Buy' Rating | SMMT Stock News - GuruFocus
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Aug Selloffs: Is Summit Therapeutics Inc impacted by rising ratesQuarterly Market Review & High Accuracy Swing Trade Signals - baoquankhu1.vn
Stifel initiates Summit Therapeutics stock with buy rating By Investing.com - Investing.com Canada
Stifel Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $45 - Moomoo
Sentiment Recap: Does Summit Therapeutics Inc have a sustainable dividendInsider Buying & Expert Curated Trade Ideas - baoquankhu1.vn
Summit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025 - MSN
Aberdeen Group plc Reduces Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics (SMMT) asks shareholders to approve 8M-share Plan increase - Stock Titan
Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab - MSN
Chart Watch: Whats next for Summit Therapeutics Inc stockEarnings Beat & Long-Term Growth Plans - baoquankhu1.vn
We're Not Very Worried About Summit Therapeutics' (NASDAQ:SMMT) Cash Burn Rate - Moomoo
Does Summit Therapeutics (SMMT) Expanding Ivonescimab Trials Clarify Its Single-Asset Oncology Strategy? - simplywall.st
Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now - AOL.com
(SMMT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Summit Therapeutics Inc Azioni (SMMT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.19%
0.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):